US approval gives Jemperli a treatment niche
However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.
ASCO 2023 – Morpheus spurs Roche to take the red pill
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.
ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
ASCO 2023 – ovarian cancer could provide a role for immuno-oncology at last
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.
ASCO 2023 – in Lag3 Regeneron could beat Bristol Myers Squibb
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
